A prospective, open-label, multi-cohort, phase II clinical study of vibecotuotamab combined with tislelizumab plus chemotherapy for esophageal squamous cell carcinoma

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 0bc87398bbf814225b9f65be2fd771106feca5be
First added on: Sep 12, 2026